Abstract
Objectives : Ginsenosidcs from Panax ginseng are metabolized by human intestinal bacteria after oral administration of ginseng extract. 20-0-($\beta-D-glucopyranosyl$)-20(S)-protopanaxadiol (Glc PPD) and 20(S)-Protopanaxatriol (PPT) are reported as the major intestinal metabolites of ginsenosides. However, the pharmaco-logical effects of Glc-PPD and PPT are not yet evaluated. The aim of this study, therefore, is to investigate whether Glc-PPD and PPT could affect the releases of interferon-$\gammer(IFN-\gammer)$ and interlcukin 10 (IL-10), two important cytokines which can regulate immune function, by activated T cells and the productions of nitric oxide (NO) and prostaglandin E2 (PGE2), two effector molecules that mediate inflammatory processes, by activated macrophages. Methods: Cytokines produced by human jurkat T cells activated with concanavalin A were measured by enzyme-linked immunosorbent assay (ELISA). No and PGE2 produced by murine RAW 264.7 macrophage activated with lipopolysaccharide were measured by Griess reagent and ELISA, respectively. Results: PPT reduced dose-dependently $IFN-\gammer$ and IL-10 releases by T cells stimulated with the mitogen concanavalin A. PPT also inhibited NO and PGE2 productions by RAW 264.7 cells stimulated with the endotoxin lipopolysaccharide. Unlike PPT, Glc-PPD had no effect on either T cell-mediated cytokine release or macrophage mediated effector molecule production. Conclusion: These results suggest that PPT may be developed as a useful agent for regulating immune responses and curing inflammatory diseases.